ArticlemedRxiv : the preprint server for health sciences2026
A longitudinal study of age-related traits and cognitive function: The Collaborative Amish Aging and Memory Project (CAAMP).
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
introductionThe Collaborative Amish Aging and Memory Project (CAAMP) is an ongoing longitudinal study spanning multiple sites, focused on cognitive function and age-related traits in Midwestern Amish (Ohio and Indiana) communities. The primary traits of interest include Alzheimer Disease and related dementias (ADRD), successful aging (SA), and other age-related conditions.
methodsCAAMP integrates clinical and cognitive assessments with family history, genealogical, genomic, biospecimen, and biomarker data collected across Amish communities in Ohio and Indiana. Cognitive diagnoses are assigned through consensus adjudication using clinical, cognitive, functional, and informant data.
resultsTo date, CAAMP has enrolled 3,978 participants (mean age 78.6 (SD = 7.9), 59.1% female, and 83% with an education level at the eighth grade), of whom 2,928 have consensus-adjudicated cognitive status. At the most recent assessment, 66.6% were cognitively unimpaired, 9.9% had mild cognitive impairment, 8.9% had Alzheimer disease, and 4.5% had cognitive impairment, but not Alzheimer disease. The remaining 1,050 did not have detailed cognitive evaluations at their enrollment. Longitudinal cognitive assessments and multiple biospecimen sample types are available for subsets of participants. CAAMP further includes extensive multigenerational pedigree information, genome-wide genotype and whole-genome sequencing data, and plasma biomarker measurements. DISCUSSION: CAAMP illuminates the genetic underpinnings of cognition and late life diseases, particularly Alzheimer Disease, by leveraging the special characteristics of a founder population. Continued study of this prospective cohort provides opportunities to identify the genetic and biological factors driving cognitive outcomes alongside other age-related conditions, advancing our understanding of both disease risk and protection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.